SureTrader
Interactive Brokers Advertisement
SureTrader
Home > Boards > US OTC > Biotechs >

U.S. Stem Cell Inc. (USRM)

USRM RSS Feed
Add USRM Price Alert      Hide Sticky   Hide Intro
Moderator: 4toSchool, BooDog, Go-Gold, TheHungryHippo, BluSkies, Rdy1
Search This Board: 
Last Post: 6/28/2017 5:59:16 PM - Followers: 865 - Board type: Free - Posts Today: 135


http://us-stemcell.com/en/home-2/
http://stemcellcoe.com
http://usstemcellclinic.com/en/home/
https://www.usstemcelltraining.com
http://www.vetbiologics.com



A COMMITMENT TO EXCELLENCE

US. Stem Cell, Inc. is committed to the discovery and development of autologous cellular therapies to treat a variety of degenerative diseases, as well as the continuation of our ongoing research for the treatment of heart failure, cardiovascular and perioheral vascular disease. 

 


The US. Stem Cell Inc. Vision
Our vision is to improve the quality of patients’ lives, while reducing hospitalizations and healthcare costs. 
Bioheart is and will continue to be recognized by physicians and patients as the world’s leader in providing 
innovative treatment and management of patients with severe cardiovascular and peripheral vascular 
disease. We are also focused on the discovery, development and commercialization of autologous cell therapies 
for the treatment of degenerative diseases.

 

.

Management:

Mike Tomás

President & CEO

Mike Tomas. Mr. Mike Tomas was appointed President and Chief Executive Officer and a member of our Board of Directors on June 19, 2010. Mike Tomas was appointed as the Company’s President and Chief Executive Officer, and as a director on June 19, 2010. Mr. Tomas has been President for the past nine years of The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart since 2001. In 2003, he joined Bioheart’s Board of Directors as the independent representative of The ASTRI Group. ASTRI provides capital, business development and strategic marketing support to emerging private companies. Mr. Tomas will continue to serve as President of The ASTRI Group. Previously from 1983 to 2001, Mr. Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a $1 billion dollar joint venture with MCI. Upon retiring from MCI and WorldCom, Tomas joined other ex-MCI executives and helped raise $40M in venture capital to form Ineto, an integrated customer communications software solution that was successfully sold in 2001.
 
Mr. Tomas sits on the boards of Avisena (revenue cycle management company for medical practices), SilverSky (fka Perimeter Internetworking) (SaaS/managed security services provider for medical practices and financial institutions), Rokk3r Labs (a digital and mobile products developer and portfolio), Bioheart (adult stem cell development for heart muscle tissue repair) and is the current chairman of Florida International University’s Global Entrepreneurship Center. He is an inductee into the Miami-Dade College and WACE Halls of Fame for business, an FIU Torch Award winner — and winner of top communications, medical innovations, education and entrepreneurial awards. Mr. Tomas holds a Masters of Business Administration from the University of Miami and a Bachelor’s degree from Florida International University.
 

Kristin Comella

Chief Scientific Officer

Kristin Comella. Ms. Comella was appointed Chief Scientific Officer in September 2010. Ms. Comella has served as our Vice President of R&D and Corporate Development since December 2008 and has played a major role in managing our product development, manufacturing and quality systems since joining Bioheart in 2004. Ms. Comella has 15 years of industry experience with expertise in regenerative medicine, training and education, research and product development, and currently serves on multiple advisory boards in the stem cell arena. Ms. Comella has many years of cell culturing experience including building and managing the stem cell laboratory at Tulane University's Center for Gene Therapy and developing stem cell therapies for osteoarthritis at Osiris Therapeutics. Ms. Comella holds an M.S. in Chemical Engineering from The Ohio State University and a B.S. in Chemical Engineering from the University of South Florida.  On March 12, 2013, Kristin Comella was appointed to serve as a member of our Board of Directors.
 

Dr. William P. Murphy, Jr.

William P. Murphy, Jr., M.D. Dr. Murphy has served as a member of our Board of Directors since June 2003. Dr. Murphy founded Small Parts, Inc., a supplier of high quality mechanical components for design engineers, in 1964 and served as its Chairman until his retirement in April 2005. Small Parts, Inc. was acquired by Amazon.com, Inc. in March 2005. From October 1999 until October 2004, Dr. Murphy served as the Chairman and Chief Executive Officer of Hyperion, Inc., a medical diagnosis company which had an involuntary bankruptcy filed against it in December 2003. Dr. Murphy is the founder of Cordis Corporation (now Cordis Johnson & Johnson) which he led as President, Chairman and Chief Executive Officer at various times during his 28 years at Cordis until his retirement in October 1985. Cordis Johnson & Johnson is a leading firm in cardiovascular instrumentation. Dr. Murphy received an M.D. in 1947 from the University of Illinois and a B.S in pre-medicine from Harvard College in 1946. He also studied physiologic instrumentation at Massachusetts Institute of Technology, or MIT. After a two year rotating internship at St. Francis Hospital in Honolulu, he became a Research Fellow in Medicine at the Peter Bent Brigham Hospital in Boston where he was the dialysis engineer on the first clinical dialysis team in the United States. He continued as an Instructor in Medicine and then a research associate in Medicine at Harvard Medical School. Dr. Murphy is the author of numerous papers and owns 17 patents. He is the recipient of a number of honors, including the prestigious Lemelson-MIT Lifetime Achievement Award, the MIT Corporate Leadership Award, the Distinguished Service Award from North American Society of Pacing and Electrophysiology, and the Jay Malina Award from the Beacon Council of Miami, Florida. He is also a member of the Inventors Hall of Fame
 

 

Executive Officers and Directors

Set forth below is information regarding our executive officers and directors as of December 31, 2013

Mike Tomas 48 Director, President and Chief Executive Officer, Chief Financial Officer
William P. Murphy, Jr., M.D. 90 Director, Chairman of the Board
Mark P. Borman  59  Director
Gregory Knutson 59 Director
Kristen Comella  37 DirectorChief Scientific Officer
Sheldon T. Anderson 63 Director
     
     

 

 

About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.


Business Strategy

 Our principal objective is to become a leading regenerative medicine company that discovers, develops and commercializes novel, autologous cell therapies, and related devices, for the treatment and improved care of patients suffering from chronic and acute heart damage as well as lower limb ischemia. Our secondary objective is the discovery, development and commercialization of autologous cell therapies for the treatment of degenerative diseases.  The number of heart failure patients is expected to increase from 25 million worldwide today to over 50 million in five years. Our focus is on serving these patients. To achieve our primary objective, we plan to pursue the following strategies:

  • - Obtain initial regulatory approval of MyoCell and/or MyoCell SDF-1 by targeting patients with severe heart damage. 
    - Continue existing studies with adipose derived stem cells and endothelial progenitor cells.
    - Continue to develop our pipeline of cell-based therapies and related devices for the treatment of chronic and acute heart damage. 
    - Develop our sales and marketing capabilities. 
    - Continue to refine our MyoCell and MyoCell SDF-1 cell culturing processes.
    - Expand and enhance our intellectual property rights.
    - License, acquire and/or develop complementary products and technologies. 


     
     
     




    Sunrise, FL – April 10, 2017 – U.S. Stem Cell, Inc. (USRM), a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies for human and animal patients, has received reactivation status of the MARVEL phase II/III trial.

    Following the passing of the 21st Century Cures Act, U.S. Stem Cell, Inc. has applied to the FDA for Regenerative Medicine Advanced Therapy (RMAT) Designation for the MyoCell product as part of the MARVEL trial.  Our trial had previously been placed on “Inactive Status” as patients were not actively being enrolled.  We placed a request to the FDA to reactivate the protocol and consider the therapy for RMAT designation.  We have recently heard from the FDA who has notified us that the protocol has been placed on “Reactivation Status” after reviewing details on the protocol and data collected on patients to date.  The FDA has also notified us that they are still reviewing our submission for RMAT.  Thanks to the REGROW component of the Cures Act, The FDA will grant RMAT designation for a regenerative medicine therapy that is intended to treat, modify, reverse, or cure a serious or life-threatening disease and demonstrates preliminary clinical evidence that the product has the potential to address unmet medical needs for a disease.  We believe that our MyoCell product meets these requirements as we have demonstrated clinical efficacy in both preclinical and clinical studies including our most recent MARVEL trial publication (review full publication here: https://www.ncbi.nlm.nih.gov/pubmed/21982657).  If RMAT designation is granted, this could expedite the approval process with the FDA.

    More information on the FDA’s new RMAT Designation can be found here: https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ucm537670.htm


     
    
USRM - Daily Candlesticks






 

USRM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
USRM News: Quarterly Report (10-q) 05/02/2017 04:06:21 PM
USRM News: Significant Updates on the Following Companies and New Coverage 04/20/2017 09:00:00 AM
USRM News: Grey Cloak Tech, Inc. (OTC Pink: GRCK), Acquires $6.4mm ShareRails, Inc. – $1.7 million in Sales, 300% Growth 04/12/2017 08:49:04 AM
USRM News: Grey Cloak Tech, Inc. (OTC Pink: GRCK), Acquires $6.4mm ShareRails, Inc. – $1.7 million in Sales, 300% Growth 04/12/2017 08:47:59 AM
USRM News: Statement of Changes in Beneficial Ownership (4) 03/31/2017 04:02:24 PM
PostSubject
#71576  Sticky Note QUOTE LOL, Hippo DD info found here! sdave2002 06/22/17 03:42:36 PM
#70960  Sticky Note Quote LOL, "Well they have time to take Hornet Driver 06/20/17 01:59:15 PM
#70115  Sticky Note MyoCell therapy "$35,000 to $45,000 range" per patient TheHungryHippo 06/19/17 12:14:48 AM
#70057  Sticky Note http://us-stemcell.com/en/june-is-off-to-an-amazing-start/ CEO Blog: June is TheHungryHippo 06/18/17 10:57:39 PM
#72576   Guessing sideways next couple days then we will TooYoungToDie 06/28/17 05:59:16 PM
#72575   That nickel test was inevitable. eheiser 06/28/17 05:42:35 PM
#72574   Unbelievable cheap shares. I remember I bought a linlinktao 06/28/17 04:01:04 PM
#72573   Not me today. I add 200k at 0.54 linlinktao 06/28/17 03:57:42 PM
#72572   Hammer tdy (good after consolidate), rsi 42 (good), Braden32601 06/28/17 03:57:13 PM
#72570   Did not test 8 but 5. Just sad!!! linlinktao 06/28/17 03:51:47 PM
#72568   REGEN trial, CEO DEFUNDED, PATIENT SAFETY CONCERNS: Hornet Driver 06/28/17 03:36:02 PM
#72567   Good observation ! I believe it would fly eheiser 06/28/17 03:30:36 PM
#72566   Perfect, dropped the rsi to 42, making lots TooYoungToDie 06/28/17 03:25:26 PM
#72565   everybody off the ask, and let her fly...USRM dirtydozen911 06/28/17 03:21:17 PM
#72564   The Classic trigger stop losses, steal shares, then TooYoungToDie 06/28/17 03:19:34 PM
#72561   ? I've posted once I was confident during Archery Class 06/28/17 02:51:50 PM
#72560   GOING CONCERN WARNINGS, LIQUIDITY PROBLEMS !! Hornet Driver 06/28/17 02:50:28 PM
#72559   You guys tell me? Your the ones chanting Ryguy008 06/28/17 02:47:39 PM
#72558   How do we explain if it does break Archery Class 06/28/17 02:46:49 PM
#72557   Myocell NO LONGER EVEN UNDER PATENT, LOL !! Hornet Driver 06/28/17 02:41:55 PM
#72556   Been saying it multiple times now... we won't Ryguy008 06/28/17 02:41:25 PM
#72554   Sounds familiar, something I posted earlier? Volume is sdave2002 06/28/17 02:29:28 PM
#72553   https://insiderfinancial.com/markets-have-overlooked-the-importance-of-the-lates TooYoungToDie 06/28/17 02:29:22 PM
#72552   I'm seeing a double bottom on the 30 caltr0m 06/28/17 02:26:19 PM
#72551   Gonna consolidate for a day or 2 around TooYoungToDie 06/28/17 02:21:25 PM
#72550   A new nice article, it should bring new saleen1563 06/28/17 01:48:59 PM
#72549   It said something like hold your shares and Moke31 06/28/17 01:38:07 PM
#72548   What did today's blog basically say? I wasn't Braden32601 06/28/17 01:31:02 PM
#72547   0.03 to 0.05. Nice profit. davidegoh 06/28/17 01:24:45 PM
#72546   Niceeee Rsi cooling for next leg$$$$ TooYoungToDie 06/28/17 01:18:48 PM
#72545   TX news would be outstanding...lots in the works Braden32601 06/28/17 01:18:05 PM
#72544   Nice Slaps, tear it down$$$$ TooYoungToDie 06/28/17 01:12:49 PM
#72543   Looks like someone is trying to load before TooYoungToDie 06/28/17 01:11:50 PM
#72542   Exactly... the trend should most likely continue. They Ryguy008 06/28/17 01:09:04 PM
#72541   But social media usually followed up with news docprep 06/28/17 01:08:25 PM
#72540   Another poorly written piece of writing from USRM Ryguy008 06/28/17 01:07:16 PM
#72539   Did it get filled?? docprep 06/28/17 01:07:08 PM
#72538   Tweet is missing a word. (Be) docprep 06/28/17 01:06:37 PM
#72537   Yep or bleed Ryguy008 06/28/17 12:47:24 PM
#72536   Looks we are going to stay at 6 linlinktao 06/28/17 12:45:03 PM
#72535   Your welcome. Ryguy008 06/28/17 12:29:06 PM
#72534   New blog today.... rocketRider 06/28/17 12:25:38 PM
#72533   https://twitter.com/USStemCellInc Ryguy008 06/28/17 12:24:51 PM
#72532   They are trying to build a wall....no chance$$$$ TooYoungToDie 06/28/17 12:14:46 PM
#72531   Red to Green baby kaching ;-) $USRM StockWhale 06/28/17 12:14:27 PM
#72530   1.5 million on CSTI Bid. caltr0m 06/28/17 12:07:40 PM
#72529   FILLED ME IN RED AND IN PIECES. ...THIS rocketRider 06/28/17 12:05:55 PM
#72528   I have order right now for .0613 NOT SHOWING!! rocketRider 06/28/17 12:04:09 PM
#72527   Gobble Gobble Gobble Weeeeeee$$$$$ TooYoungToDie 06/28/17 12:03:38 PM
#72526   Lets go green$. Still holding strong here. Zues 06/28/17 12:02:31 PM
#72525   You think we may see USRM going into ROCKER67 06/28/17 12:02:24 PM
#72524   Red to Green Amazing strength here$$$$ TooYoungToDie 06/28/17 12:01:08 PM
#72523   only 100K to .068 BUY!!! docprep 06/28/17 12:00:47 PM
#72522   ILL DO THAT TILL .50 UNLESS IM FILLED SOONER. rocketRider 06/28/17 11:59:37 AM
PostSubject